SIGHT SCIENCES INC (SGHT)
US82657M1053 - Common Stock
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the...
Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma
The analysis published in Clinical Ophthalmology suggests that OMNI was as effective at lowering IOP and reducing medication usage in advanced glaucoma as...
SGHT Stock Earnings: Sight Sciences Misses EPS, Beats Revenue for Q1 2024
SGHT stock results show that Sight Sciences missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
SGHT Stock Earnings: Sight Sciences Misses EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sight Sciences (NASDAQ:SGHT) just reported results for the first quarter of 202...
Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance
MENLO PARK, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery
MENLO PARK, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on...
Sight Sciences to Report First Quarter Financial Results on May 2, 2024
MENLO PARK, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology...
Sight Sciences gibt die Veröffentlichung einer groß angelegten, praxisnahen MIGS-Studie als Nachweis für die Wirksamkeit des umfassenden Verfahrens zur Wiederherstellung des Kammerwasserabflusses mit der OMNI® Surgical System-Technologie sowohl bei der
Die Wirksamkeit der drei am häufigsten verwendeten MIGS-Technologien in Kombination mit einer Kataraktoperation und der Kataraktoperation allein wurde an...
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2
The efficacy of the three most commonly used MIGS technologies in combination with cataract surgery and cataract surgery alone were evaluated and compared...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic this morning as we check out all of the biggest news worth reading about on Wednesday morning!
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Clinical results demonstrate long-term efficacy of the OMNI® Surgical System for primary open-angle glaucoma and support use of TearCare® technology as a...
Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference
MENLO PARK, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology...
SGHT Stock Earnings: Sight Sciences Beats EPS, Misses Revenue for Q4 2023
SGHT stock results show that Sight Sciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
SGHT Stock Earnings: Sight Sciences Beats EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sight Sciences (NASDAQ:SGHT) just reported results for the fourth quarter of 20...
Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance
MENLO PARK, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (
Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024
MENLO PARK, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology...
Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting
MENLO PARK, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (
Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital
Refinancing replaces prior senior credit facility...
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
MENLO PARK, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (
Sight Sciences says no change in Medicare coverage for OMNI
Sight Sciences' (SGHT) OMNI Surgical System retains Medicare coverage for glaucoma surgeries, as Medicare Administrative Contractors pull back. Read more here.
Sight Sciences says no change in Medicare coverage for OMNI (NASDAQ:SGHT)
Sight Sciences' (SGHT) OMNI Surgical System retains Medicare coverage for glaucoma surgeries, as Medicare Administrative Contractors pull back. Read more here.
Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors
Decision ensures continued access to comprehensive outflow procedure enabled by OMNI® Surgical System technology for glaucoma patients...
Sight Sciences stock climbs on glaucoma procedure update (NASDAQ:SGHT)
Sight Sciences (SGHT) surged 43% as Wells Fargo dismissed concerns about Medicare coverage for its glaucoma surgical procedure. Read more here.
Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease
Interventional eyelid procedures enabled by TearCare technology successfully delivered clinically and statistically significant improvements in every sign...
Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology
Prospective, long-term trial results are consistent with the significant body of published clinical evidence demonstrating the durable safety and...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start of the trading week with a look at the biggest pre-market stock movers worth watching on Monday morning!
5 Risky Stocks to Buy Immediately, According to AI
Man and machine are combining to recommend these 5 risky stocks to buy. Here are some of the top picks to add now.
Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023
MENLO PARK, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (